Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …

Rivaroxaban has been widely used to prevent and treat various thromboembolic diseases
for more than a decade. However, whether a lower dose of rivaroxaban is required for …

Rivaroxaban, a direct factor Xa inhibitor, is widely used for stroke prevention in patients with
non-valvular atrial fibrillation (NVAF). The aim of this study was to conduct a population …

Low-dose rivaroxaban has been used in Asian patients with direct oral anticoagulants
(DOACs) eligible for atrial fibrillation (AF). However, there are few pharmacokinetic (PK) data …

Background The effectiveness and safety of dabigatran etexilate (DE) have not been
elucidated thoroughly in clinical practice for Japanese patients with non-valvular atrial …

Background and Purpose—We compared the 1-year safety and effectiveness of rivaroxaban
15 mg (R15) or rivaroxaban 20 mg (R20) to vitamin K antagonists (VKAs) in patients with …

Background The ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition
Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial …

This retrospective study investigated factors influencing the steady-state trough
concentrations (C trough) of rivaroxaban in patients with nonvalvular atrial fibrillation …

Objective To evaluate the efficacy and safety of oral anticoagulants for older adult patients
with atrial fibrillation (AF). Design Pairwise and network meta-analyses. Setting and …

Dabigatran and rivaroxaban at standard or reduced doses have been compared to warfarin
in nonvalvular atrial fibrillation (NVAF), but not to each other. This was a new user study of …